Novartis AG (NVS) – Aiming to disrupt biosimilar space

Sandoz, a Novartis division, entered into a commercialization agreement with Bio Thera Solutions, Ltd. for biosimilar bevacizumab in Sep 21. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody, a key mediator of angiogenesis in cancer, and is used in combination with other treatments.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 36